KRAS mutation – Medxy AI

KRAS-Driven CLDN18.2 O-GlcNAcylation Promotes Pancreatic Cancer Progression and Therapy Resistance

By MedXY 05/16/2026

KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.

Clinical Updates news Oncology

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY 09/19/2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.

Clinical Updates news Oncology Specialties

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

By MedXY 09/08/2025

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.